<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02057887</url>
  </required_header>
  <id_info>
    <org_study_id>HM-IFN-201</org_study_id>
    <nct_id>NCT02057887</nct_id>
  </id_info>
  <brief_title>Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of multiple ascending
      doses of HM10660A in subjects with chronic hepatitis C(HCV).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To evaluate the repeat-dose pharmacokinetics (PK) of HM10660A when given by weekly,
           biweekly, and monthly subcutaneous (SC) injection.

        -  To evaluate the repeat-dose pharmacodynamics (PD) of HM10660A when given by weekly,
           biweekly, and monthly SC injection.

        -  To explore the antiviral activity of HM10660A at Week 4, Week 12, and Week 24.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HCV RNA Viral load</measure>
    <time_frame>Through study week 32</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety/tolerability</measure>
    <time_frame>Through study week 32</time_frame>
    <description>symptom-directed physical examination, Vital signs, Inspection of the Injection site, Complete Physical examination, 12-lead ECG, Hematology/coagulation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rapid virologic response (RVR)</measure>
    <time_frame>Study Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early virologic response (EVR)</measure>
    <time_frame>Study week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained virologic response (SVR)</measure>
    <time_frame>Study week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Chronic Hepatitis C Virus Genotype I</condition>
  <arm_group>
    <arm_group_label>Cohort1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HM10660A SC once weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HM10660A SC once every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HM10660A SC once every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>180 mcg Pegasys SC once weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM10660A</intervention_name>
    <arm_group_label>Cohort1</arm_group_label>
    <arm_group_label>Cohort2</arm_group_label>
    <arm_group_label>Cohort3</arm_group_label>
    <other_name>Laps-IFNa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegasys</intervention_name>
    <description>180 mcg Pegasys SC once weekly</description>
    <arm_group_label>Cohort4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 18 to 65 years old, inclusive

          -  Willing and able to provide written informed consent.

          -  Previously untreated HCV infection with HCV RNA &gt; 75,000 IU/mL at screening.

          -  HCV genotype 1a or 1b.

          -  Body mass index (BMI) between 18 and 38 kg/m2.

          -  Willing and able to comply with the protocol and available to complete the study
             schedule of assessments.

        Exclusion Criteria:

          -  Pregnant women or women who may wish to become pregnant during the course of the
             study.

          -  Males and females of reproductive potential who are unwilling to use 2 forms of
             effective birth control throughout the duration of study treatment and for at least 6
             months after the last dose of RBV. One method should include a condom with spermicide
             for males. Males must agree to refrain from sperm donation for at least 6 months after
             the last dose of RBV.

          -  Evidence of infection or co-infection with a non-genotype 1 HCV strain.

          -  Co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV).

          -  Lactating females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hanmi Clinical</last_name>
    <email>clinical4@hanmi.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hanmi Clinical</name>
      <address>
        <city>Estado de Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanmi Clinical</last_name>
      <email>clinical4@hanmi.co.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2013</study_first_submitted>
  <study_first_submitted_qc>February 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2014</study_first_posted>
  <last_update_submitted>February 6, 2014</last_update_submitted>
  <last_update_submitted_qc>February 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

